HK1257199A1 - 用於檢測cd37的抗體和測定 - Google Patents

用於檢測cd37的抗體和測定

Info

Publication number
HK1257199A1
HK1257199A1 HK18116201.1A HK18116201A HK1257199A1 HK 1257199 A1 HK1257199 A1 HK 1257199A1 HK 18116201 A HK18116201 A HK 18116201A HK 1257199 A1 HK1257199 A1 HK 1257199A1
Authority
HK
Hong Kong
Prior art keywords
assays
antibodies
detection
Prior art date
Application number
HK18116201.1A
Other languages
English (en)
Inventor
Jutta Deckert
Daniel Tavares
Lingyun Rui
Sven Loebrich
Meghan Kelly
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of HK1257199A1 publication Critical patent/HK1257199A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HK18116201.1A 2015-08-28 2018-12-18 用於檢測cd37的抗體和測定 HK1257199A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562211455P 2015-08-28 2015-08-28
US201562212183P 2015-08-31 2015-08-31
PCT/US2016/048887 WO2017040247A1 (en) 2015-08-28 2016-08-26 Antibodies and assays for detection of cd37

Publications (1)

Publication Number Publication Date
HK1257199A1 true HK1257199A1 (zh) 2019-10-18

Family

ID=58188089

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116201.1A HK1257199A1 (zh) 2015-08-28 2018-12-18 用於檢測cd37的抗體和測定

Country Status (15)

Country Link
US (1) US11104740B2 (zh)
EP (1) EP3341414A4 (zh)
JP (1) JP6890581B2 (zh)
KR (1) KR20180042423A (zh)
CN (1) CN108699144B (zh)
AU (1) AU2016316758B2 (zh)
BR (1) BR112018003147A2 (zh)
CA (1) CA2995243A1 (zh)
EA (1) EA201890347A1 (zh)
HK (1) HK1257199A1 (zh)
IL (1) IL257354B2 (zh)
MA (1) MA42706A (zh)
MX (1) MX2018002467A (zh)
SA (1) SA518391028B1 (zh)
WO (1) WO2017040247A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3620467A1 (en) 2010-03-12 2020-03-11 Debiopharm International SA Cd37-binding molecules and immunoconjugates thereof
CN105999293B (zh) 2011-04-01 2019-07-23 德彪发姆国际有限公司 Cd37结合分子及其免疫缀合物
AU2016276158B2 (en) 2015-06-08 2022-06-30 Debiopharm International, S.A. Anti-CD37 immunoconjugate and anti-CD20 antibody combinations
WO2017040247A1 (en) 2015-08-28 2017-03-09 Immunogen, Inc. Antibodies and assays for detection of cd37
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5977316A (en) 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
IL153764A0 (en) 2000-07-12 2003-07-06 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
KR20080087184A (ko) 2001-01-31 2008-09-30 바이오겐 아이덱 인크. 종양질환 치료를 위한 ｃｄ23 길항제의 용도
EP1372724A2 (en) 2001-01-31 2004-01-02 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
WO2002102972A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CN100339395C (zh) 2001-11-08 2007-09-26 养生堂有限公司 戊型肝炎病毒单克隆抗体及其用途
WO2003048306A2 (en) 2001-11-16 2003-06-12 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
CA2505717A1 (en) 2002-11-15 2004-06-03 Immunomedics, Inc. Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics
JP4959136B2 (ja) 2002-12-13 2012-06-20 イミューノメディクス、インコーポレイテッド 細胞内で開裂可能な結合を有する免疫接合体
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
KR101412271B1 (ko) 2003-05-09 2014-06-25 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US7241598B2 (en) * 2004-06-29 2007-07-10 The Chinese University Of Hong Kong Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
EP1784425A4 (en) * 2004-06-30 2009-02-18 Centocor Inc ANTI-MCP-1 ANTIBODIES, COMPOSITIONS, METHODS AND USES
EP1838736B1 (en) 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto binding molecules
KR101363120B1 (ko) 2005-02-10 2014-02-13 베일러 리서치 인스티튜트 항-인터페론 알파 모노클로날 항체 및 사용 방법
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
CA2608835A1 (en) 2005-05-20 2006-11-30 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
WO2006133450A2 (en) 2005-06-08 2006-12-14 Duke University Anti-cd19 antibody therapy for the transplantation
US20080279850A1 (en) 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
EP2298815B1 (en) 2005-07-25 2015-03-11 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
EP2447282B1 (en) 2006-05-30 2016-01-27 Genentech, Inc. Anti-CD22 Antibodies, their Immunoconjugates and uses thereof
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
MX2009001110A (es) 2006-08-03 2009-05-11 Vaccinex Inc Anticuerpos monoclonales anti-il-6 y usos de los mismos.
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
EP2076538A2 (en) 2006-10-24 2009-07-08 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
US20090148447A1 (en) 2007-07-06 2009-06-11 Trubion Pharmaceuticals, Inc. Binding Peptides Having a C-terminally Disposed Specific Binding Domain
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
GB2454915B (en) 2007-11-23 2012-02-15 Schlumberger Holdings Spooling apparatus for well intervention system
WO2009085573A2 (en) 2007-12-28 2009-07-09 Spring Bioscience Corporation Quality control cell device for immunohistochemistry assay and methods of use thereof
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US7740844B2 (en) * 2008-04-29 2010-06-22 Taiwan Liposome Co. Ltd Anti-VEGF monoclonal antibody
LT2281006T (lt) 2008-04-30 2017-11-27 Immunogen, Inc. Skersinių jungčių linkeriai ir jų panaudojimas
AU2009271401A1 (en) 2008-06-16 2010-01-21 Immunogen Inc. Novel synergistic effects
US8900589B2 (en) 2008-07-15 2014-12-02 Genetech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
CA2743487A1 (en) 2008-11-13 2010-05-20 Emergent Product Development Seattle, Llc Cd37 immunotherapeutic combination therapies and uses thereof
EP2486023A4 (en) 2009-10-06 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
PL2519543T3 (pl) 2009-12-29 2016-12-30 Białka wiążące heterodimery i ich zastosowania
AR080155A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos anti-cd20 y su utilizacion
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
EP3620467A1 (en) 2010-03-12 2020-03-11 Debiopharm International SA Cd37-binding molecules and immunoconjugates thereof
US8349585B2 (en) 2010-04-15 2013-01-08 Alper Biotech, Llc Monoclonal antibodies against HER2 antigens, and uses therefor
KR20220123130A (ko) * 2011-03-29 2022-09-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
CN105999293B (zh) 2011-04-01 2019-07-23 德彪发姆国际有限公司 Cd37结合分子及其免疫缀合物
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
SG11201403134PA (en) * 2011-12-13 2014-07-30 Nordic Nanovector As Chimeric therapeutic anti - cd37 antibodie hh1
EP2831585A4 (en) 2012-03-30 2015-12-02 Immunogen Inc METHODS OF INCREASING THE EFFECTIVENESS OF THERAPY BASED ON CD37
US20130309224A1 (en) 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with rituximab
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
SI2900277T1 (sl) 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
WO2014143807A2 (en) 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
CN108939065A (zh) 2013-06-07 2018-12-07 诺帝克纳诺维科特公司 用于上调抗原表达的方法
RU2675824C2 (ru) 2013-09-11 2018-12-25 Игл Байолоджикс, Инк. Жидкие белковые составы, содержащие ионные жидкости
JP6478989B2 (ja) 2013-11-07 2019-03-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｃｄ２０抗体とｂｔｋ阻害剤とを用いた併用療法
WO2015116729A2 (en) 2014-01-28 2015-08-06 Emergent Product Development Seattle, Llc Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders
US20150343077A1 (en) 2014-05-13 2015-12-03 Immunogen, Inc. Anti-CD37 Immunoconjugate Dosing Regimens
AU2016276158B2 (en) 2015-06-08 2022-06-30 Debiopharm International, S.A. Anti-CD37 immunoconjugate and anti-CD20 antibody combinations
WO2017040247A1 (en) 2015-08-28 2017-03-09 Immunogen, Inc. Antibodies and assays for detection of cd37
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
CA3101790A1 (en) 2018-05-30 2019-12-05 Debiopharm International, S.A. Anti-cd37 immunoconjugate dosing regimens

Also Published As

Publication number Publication date
KR20180042423A (ko) 2018-04-25
AU2016316758B2 (en) 2023-02-02
US20180244795A1 (en) 2018-08-30
CN108699144A (zh) 2018-10-23
JP2018532699A (ja) 2018-11-08
SA518391028B1 (ar) 2022-07-19
WO2017040247A1 (en) 2017-03-09
MA42706A (fr) 2021-04-14
MX2018002467A (es) 2018-06-15
IL257354B1 (en) 2023-04-01
AU2016316758A1 (en) 2018-03-15
IL257354A (en) 2018-04-30
CA2995243A1 (en) 2017-03-09
IL257354B2 (en) 2023-08-01
EA201890347A1 (ru) 2018-09-28
BR112018003147A2 (pt) 2018-09-18
CN108699144B (zh) 2022-07-19
US11104740B2 (en) 2021-08-31
JP6890581B2 (ja) 2021-06-18
EP3341414A4 (en) 2019-03-27
EP3341414A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
HK1259426A1 (zh) Pd-l1抗體及其用途
HK1255604A1 (zh) 抗pd-l1抗體及其用途
HK1258267A1 (zh) 抗前/潛在肌生長抑制素抗體及其用途
ZA201900353B (en) Anti-pd-l1 antibodies
IL262295B1 (en) Antibodies against pd–l1
HK1246324A1 (zh) 抗pd-l1抗體
ZA201902533B (en) Anti-pd-l1 antibodies and variants
HK1243940A1 (zh) 抗原肌肉生長抑制素/潛在肌肉生長抑制素的抗體及其用途
IL250415A0 (en) Antibodies against pd-l1
HK1257199A1 (zh) 用於檢測cd37的抗體和測定
HK1243489A1 (zh) 用於檢測分析物的方法和系統
HUE047156T2 (hu) Peptidek, eszközök és eljárások Anaplasma-ellenanyagok kimutatására
EP3209686A4 (en) Monoclonal anti-gpc-1 antibodies and uses thereof
EP3502686C0 (de) Antigennachweis von trichinella
GB201518675D0 (en) Detection of structural forms of proteins
IL248458A0 (en) Cry1ca-specific monoclonal antibodies and related detection methods
HK1258302A1 (zh) 用於測定fc區修飾的抗體的免疫測定法
GB201516008D0 (en) OX40L antibodies and uses thereof